Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 3,725 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 3,725 shares of the company’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.68, for a total transaction of $17,433.00. Following the completion of the sale, the insider directly owned 272,996 shares in the company, valued at $1,277,621.28. This trade represents a 1.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,944.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Trading Up 2.3%

Shares of SOPH traded up $0.11 on Tuesday, hitting $4.96. 148,768 shares of the stock traded hands, compared to its average volume of 183,135. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $339.71 million, a P/E ratio of -9.73 and a beta of 1.04. The stock’s 50 day moving average is $4.74 and its two-hundred day moving average is $4.71. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, sell-side analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC acquired a new position in SOPHiA GENETICS during the third quarter worth approximately $6,708,000. Archon Capital Management LLC increased its position in SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in SOPHiA GENETICS during the fourth quarter worth approximately $2,009,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim upped their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research reissued a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.